STOCKHOLM, Sept. 27, 2024 /PRNewswire/ -- SciBase
Holding AB ("SciBase") [STO: SCIB], pioneering
prevention and prediction in dermatology disorders
is pleased to announce the completion of a milestone sale of
Nevisense, a leading skin barrier research device, to the National
Institutes of Health (NIH), one of the world's foremost medical
research centers and a part of the U.S. Department of Health and
Human Services. This sale represents a major milestone for SciBase
and demonstrates the high quality and innovative nature of
Nevisense for research.
The device will be used to conduct research on the microbiome
and its interactions in atopic dermatitis (AD), exploring how the
microbiome may unearth new treatments for AD.
"The fact that this prestigious governmental institution has
chosen to use Nevisense in their research speaks volumes about the
credibility and reliability of our product," says Pia Renaudin, CEO of SciBase. "The skin
barrier research market is experiencing a rapid rise in interest,
and the research in this space can directly improve the lives of
millions of people worldwide. We are confident that the use of our
device by the NIH will lead to groundbreaking discoveries and
advancements in the field of dermatology."
Nevisense is, apart from being able to detect skin cancer, also
designed to analyze skin barrier function with the highest accuracy
and robustness available, making it an essential tool for
researchers. To date, studies have included Nevisense to study skin
disorders, investigate environmental irritants and their effect on
skin health, and analyze skin barrier dysfunction as it relates to
allergies.
For more information on Nevisense for research and SciBase's
medical products, visit www.scibase.com or contact
Jeremy Bost at
jeremy.bost@scibase.com .
For additional information, please contact:
Pia Renaudin, CEO, tel.
+46732069802, e-mail: pia.renaudin@scibase.com
Certified Advisor (CA):
Carnegie Investment Bank AB
(publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se
About SciBase
SciBase is a global medical technology company, specializing
on early detection and prevention in dermatology. SciBase
develops and commercializes Nevisense, a unique point-of-care
platform that combines AI (artificial intelligence) and advanced
EIS technology to enhance diagnostic accuracy, ensuring proactive
skin health management.
Our commitment is to minimize patient suffering, allowing
clinicians to improve and save lives through timely detection and
intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in
dermatological advancements.
The company has been on the Nasdaq First North Growth Market
exchange since June 2, 2015 and the
company's Certified Adviser is Carnegie Investment Bank AB (publ).
Learn more at www.scibase.com. For press
releases and financial reportsvisit:
http://investors.scibase.se/en/pressreleases
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/scibase/r/scibase-announces-sale-of-nevisense-to-nih--us-,c4043952
The following files are available for download:
https://mb.cision.com/Main/12371/4043952/3026463.pdf
|
PR NIH eng
final
|
https://news.cision.com/scibase/i/nih-2024-09-27,c3337864
|
NIH
2024-09-27
|
View original
content:https://www.prnewswire.co.uk/news-releases/scibase-announces-sale-of-nevisense-to-nih-us-302261013.html